D.E. Shaw & Co’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-53,432
| Closed | -$533K | – | 4743 |
|
|
2025
Q2 | $533K | Sell |
53,432
-50,693
| -49% | -$408K | ﹤0.01% | 3610 |
|
|
2025
Q1 | $622K | Buy |
104,125
+47,591
| +84% | +$349K | ﹤0.01% | 3366 |
|
|
2024
Q4 | $434K | Sell |
56,534
-69,227
| -55% | -$595K | ﹤0.01% | 3706 |
|
|
2024
Q3 | $1.28M | Sell |
125,761
-93,562
| -43% | -$1.43M | ﹤0.01% | 3082 |
|
|
2024
Q2 | $3.25M | Buy |
219,323
+82,603
| +60% | +$1.18M | ﹤0.01% | 2203 |
|
|
2024
Q1 | $1.86M | Sell |
136,720
-25,338
| -16% | -$276K | ﹤0.01% | 2681 |
|
|
2023
Q4 | $1.77M | Buy |
162,058
+47,600
| +42% | +$472K | ﹤0.01% | 2760 |
|
|
2023
Q3 | $1.25M | Buy |
114,458
+34,976
| +44% | +$447K | ﹤0.01% | 2923 |
|
|
2023
Q2 | $1.05M | Buy |
79,482
+6,816
| +9% | +$97.2K | ﹤0.01% | 3054 |
|
|
2023
Q1 | $989K | Buy |
72,666
+5,653
| +8% | +$101K | ﹤0.01% | 3175 |
|
|
2022
Q4 | $1.31M | Sell |
67,013
-18,732
| -22% | -$366K | ﹤0.01% | 3256 |
|
|
2022
Q3 | $1.63M | Buy |
85,745
+51,739
| +152% | +$1.19M | ﹤0.01% | 3178 |
|
|
2022
Q2 | $701K | Buy |
+34,006
| New | +$807K | ﹤0.01% | 3854 |
|
|
2021
Q2 | – | Sell |
-7,742
| Closed | -$265K | – | 4869 |
|
|
2021
Q1 | $265K | Buy |
7,742
+1,759
| +29% | +$63.6K | ﹤0.01% | 3755 |
|
|
2020
Q4 | $202K | Buy |
+5,983
| New | +$158K | ﹤0.01% | 3730 |
|
Other funds holding ITOS
D.E. Shaw & Co's ITOS Position: Q3 2025 in Review
D.E. Shaw & Co sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 53,432 shares — an estimated $533K sold.
D.E. Shaw & Co first reported a position in ITOS in Q4 2020 and held it in 15 quarters. The position peaked at $3.25M in Q2 2024. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- D.E. Shaw & Co reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- D.E. Shaw & Co sold 53,432 iTeos Therapeutics shares in Q3 2025, an estimated $533K.
- D.E. Shaw & Co first reported a position in iTeos Therapeutics in Q4 2020 and held it in 15 quarters.
- D.E. Shaw & Co's iTeos Therapeutics position peaked at $3.25M in Q2 2024.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on D.E. Shaw & Co's 13F filing for Q3 2025, filed 14 Nov 2025.